Get the Stockscreener App
26.68
5.61%
-1.5045
Rigel Pharmaceuticals stock is traded at $26.68, with a volume of 458.26K.
It is down -5.61% in the last 24 hours and down -29.93% over the past month.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
See More
Previous Close:
$28.18
Open:
$28.25
24h Volume:
458.26K
Relative Volume:
0.72
Market Cap:
$477.22M
Revenue:
$116.88M
Net Income/Loss:
$-25.09M
P/E Ratio:
-190.54
EPS:
-0.14
Net Cash Flow:
$-20.74M
1W Performance:
-7.96%
1M Performance:
-29.93%
6M Performance:
+59.47%
1Y Performance:
+72.39%
1-Day Range:
$26.53
$28.61
1-Week Range:
$26.53
$30.60
52-Week Range:
$13.57
$43.72
Rigel Pharmaceuticals Stock (RIGL) Company Profile
Name
Rigel Pharmaceuticals
Sector
Industry
Phone
650-624-1100
Address
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Compare RIGL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RIGL
Rigel Pharmaceuticals
|
26.61 | 505.47M | 116.88M | -25.09M | -20.74M | -0.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.62 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.57 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.99 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
803.71 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
330.86 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-03-23 | Resumed | Piper Sandler | Neutral |
| Jun-09-22 | Downgrade | Citigroup | Buy → Neutral |
| Jun-08-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-08-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-23-22 | Initiated | B. Riley Securities | Neutral |
| Nov-09-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-15-19 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-26-19 | Resumed | JP Morgan | Overweight |
| Mar-01-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Aug-27-18 | Initiated | Citigroup | Buy |
| May-02-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Dec-21-17 | Resumed | Piper Jaffray | Overweight |
| Dec-15-17 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-06-17 | Resumed | H.C. Wainwright | Buy |
| Mar-09-17 | Reiterated | H.C. Wainwright | Buy |
| Aug-31-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-30-16 | Reiterated | Piper Jaffray | Overweight |
| Jul-13-16 | Initiated | H.C. Wainwright | Buy |
| Jun-13-16 | Initiated | Piper Jaffray | Overweight |
| Apr-22-16 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-08-13 | Reiterated | Stifel | Buy |
| Nov-29-12 | Initiated | UBS | Neutral |
| Nov-06-12 | Reiterated | Oppenheimer | Outperform |
| Mar-26-12 | Initiated | Canaccord Genuity | Hold |
| Dec-10-10 | Downgrade | MP Advisors | Outperform → Market Perform |
View All
Rigel Pharmaceuticals Stock (RIGL) Latest News
Can Rigel Pharmaceuticals Inc. stock deliver strong Q4 earningsJuly 2025 Breakouts & Expert-Curated Trade Recommendations - newser.com
Is this a good reentry point in Rigel Pharmaceuticals Inc.July 2025 Movers & Verified Chart Pattern Trade Signals - newser.com
Is Rigel Pharmaceuticals Inc. stock a contrarian buy2025 Trading Volume Trends & Free Weekly Chart Analysis and Trade Guides - newser.com
What the charts say about Rigel Pharmaceuticals Inc. todayWeekly Investment Summary & Low Risk High Reward Trade Ideas - newser.com
Why Rigel Pharmaceuticals Inc. stock could see breakout soonMarket Performance Summary & Low Risk Investment Opportunities - newser.com
Rigel Pharmaceuticals Inc. stock volume spike explained2025 Fundamental Recap & Short-Term High Return Strategies - newser.com
Is Rigel Pharmaceuticals Inc. stock recession proofWatch List & Weekly Breakout Stock Alerts - newser.com
How Rigel Pharmaceuticals’ R289 Trial Progress and FDA Designations Will Impact RIGL Investors - Yahoo Finance
Rigel Pharmaceuticals (RIGL): Assessing Valuation Following Key Clinical Milestone for R289 - simplywall.st
Did Rigel's (RIGL) R289 Phase 1b Expansion Just Shift the Company's Pipeline Prospects? - simplywall.st
Is Rigel Pharmaceuticals Inc. stock reversal real or fakeMarket Trend Report & Safe Capital Growth Tips - newser.com
Rigel Pharmaceuticals (NASDAQ:RIGL) Receives "Hold (C+)" Rating from Weiss Ratings - MarketBeat
Rigel Pharmaceuticals stock advances as first patient enrolled in R289 study expansion - Investing.com
Multi factor analysis applied to Rigel Pharmaceuticals Inc.2025 Volume Leaders & Reliable Entry Point Alerts - newser.com
Published on: 2025-10-09 05:05:12 - newser.com
HC Wainwright & Co. Reiterates Rigel Pharmaceuticals (RIGL) Buy Recommendation - Nasdaq
H.C. Wainwright Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $57 - 富途牛牛
Rigel Pharmaceuticals (NASDAQ:RIGL) Stock Price Down 4%What's Next? - MarketBeat
Rigel Pharmaceuticals (RIGL) Rating Reiterated as 'Buy' by HC Wa - GuruFocus
Rigel Pharmaceuticals' (RIGL) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Rigel Pharmaceuticals, Inc. Announces First Patient Enrolled in the Dose Expansion Phase of its Phase 1b Study of R289 in Patients with Lower-Risk MDS - MarketScreener
Rigel Pharmaceuticals (RIGL) Advances Phase 1b Study with New Pa - GuruFocus
Rigel announces first patient enrolled in dose expansion phase of 1b study of R289 in patients with lower-risk MDS - MarketScreener
Rigel Pharmaceuticals (NASDAQ:RIGL) Downgraded to "Hold" Rating by Zacks Research - MarketBeat
First patient enrolled: Rigel advances R289 Phase 1b dose expansion, 500 mg qd/bid, up to 40 pts for RP2D - Stock Titan
Does Rigel Pharmaceuticals Inc. qualify in momentum factor screening2025 Market WrapUp & Fast Momentum Stock Entry Tips - newser.com
Will Rigel Pharmaceuticals Inc. (RI2) stock profit from fiscal stimulusWeekly Profit Report & Expert Approved Momentum Trade Ideas - newser.com
Analyzing Rigel Pharmaceuticals Inc. with multi timeframe chartsWeekly Trend Recap & Free Technical Pattern Based Buy Signals - newser.com
Applying Elliott Wave Theory to Rigel Pharmaceuticals Inc.Fed Meeting & Proven Capital Preservation Methods - newser.com
Using portfolio simulators with Rigel Pharmaceuticals Inc. included2025 Bull vs Bear & High Return Trade Opportunity Guides - newser.com
Volume spikes in Rigel Pharmaceuticals Inc. stock – what they mean2025 Stock Rankings & Expert Curated Trade Setups - newser.com
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Eastern Progress
Immune Thrombocytopenic Purpura (ITP) Pipeline 2025: Pioneering Clinical Developments by 30+ Global Leaders – DelveInsight | Featuring Sanofi, Takeda, Rigel Pharmaceuticals, Bristol-Myers Squibb - Barchart.com
Rigel Pharmaceuticals announces inducement grants - MarketScreener
A Deep Dive Into Rigel Pharmaceuticals (RIGL) Valuation After Voya Investment Management Expands Stake - simplywall.st
Rigel Pharmaceuticals (NASDAQ:RIGL) Stock Price Crosses Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
41,138 Options & 27,475 RSUs — Rigel Announces Inducement Grants to New Employees - Stock Titan
What analysts say about Rigel Pharmaceuticals Inc RI2 stockStock Buyback Updates & Free Rapid Wealth Multiplication - earlytimes.in
Voya Strengthens Position in Rigel Pharmaceuticals, Inc. (RIGL) - Insider Monkey
Can Rigel Pharmaceuticals Inc. (RI2) stock double in coming yearsJuly 2025 EndofMonth & Real-Time Stock Movement Alerts - newser.com
Can RIGL's Oncology Portfolio Create Long-Term Value Beyond Tavalisse? - sharewise.com
Should Value Investors Buy Rigel Pharmaceuticals (RIGL) Stock? - Yahoo Finance
Rigel Pharmaceuticals Stock (RIGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Rigel Pharmaceuticals Stock (RIGL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Schorno Dean L | EVP & Chief Financial Officer |
Feb 05 '25 |
Sale |
21.93 |
1,734 |
38,020 |
57,235 |
| Santos David A | EVP, Chief Commercial Officer |
Feb 04 '25 |
Sale |
20.92 |
2,125 |
44,457 |
53,500 |
| Santos David A | EVP, Chief Commercial Officer |
Feb 05 '25 |
Sale |
21.93 |
1,796 |
39,379 |
51,704 |
| RODRIGUEZ RAUL R | CEO, President |
Feb 04 '25 |
Sale |
20.92 |
4,952 |
103,601 |
243,854 |
| RODRIGUEZ RAUL R | CEO, President |
Feb 05 '25 |
Sale |
21.93 |
4,400 |
96,474 |
239,454 |
| Furey Raymond J. | EVP, GC, CCO & Corp Sec |
Feb 04 '25 |
Sale |
20.92 |
1,448 |
30,294 |
40,169 |
| Furey Raymond J. | EVP, GC, CCO & Corp Sec |
Feb 05 '25 |
Sale |
21.93 |
1,339 |
29,359 |
38,830 |
1.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):